Trial Profile
UCD0115B: An Open-label Extension Study of Purified Epicatechin to Improve Mitochondrial Function, Strength and Skeletal Muscle Exercise Response in Becker Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Epicatechin (Primary)
- Indications Duchenne muscular dystrophy
- Focus Biomarker; Pharmacodynamics
- 06 Jun 2018 Status changed from recruiting to completed.
- 04 Aug 2017 New trial record